Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19046854 | 1.00 | ABHD6 (0.41) | ABHD6SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL19046940 | 1.00 | ABHD6 (0.41) | ABHD6SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL15131035 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3OPRM1OPRK1 | |
| SCHEMBL19010138 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3OPRM1OPRK1 | |
| SCHEMBL19010135 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3OPRM1OPRK1 | |
| SCHEMBL22183794 | 0.78 | ABHD6 (0.51) | ABHD6SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL19046849 | 0.78 | ABHD6 (0.51) | ABHD6SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL1614612 | 0.77 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3PRCPCYP2D6 | |
| SCHEMBL23057926 | 0.76 | OPRM1 (0.41) | ABHD6SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL23057925 | 0.76 | OPRM1 (0.41) | ABHD6SLC6A2SLC6A4SLC6A3PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-10683304-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190169204-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683304-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | ABHD6 3567/4885SLC6A2 4724/4885SLC6A4 4275/4885 |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | ABHD6 3479/4885SLC6A2 4743/4885SLC6A4 4233/4885 |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | ABHD6 3567/4885SLC6A2 4724/4885SLC6A4 4275/4885 |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | ABHD6 3567/4885SLC6A2 4724/4885SLC6A4 4275/4885 |
| US-20190169204-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | ABHD6 3567/4885SLC6A2 4724/4885SLC6A4 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.